<DOC>
	<DOCNO>NCT00131677</DOCNO>
	<brief_summary>The purpose study examine safety tolerability daily tenofovir use HIV-uninfected men .</brief_summary>
	<brief_title>Extended Safety Study Tenofovir Disoproxil Fumarate ( TDF ) Among HIV-1 Negative Men</brief_title>
	<detailed_description>This study assess clinical behavioral safety tolerability oral daily TDF use pre-exposure prophylaxis ( PrEP ) prevent HIV infection uninfected men .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Healthy biologic male ( male birth ) 1860 year age HIV1 negative license , commercially available , FDAapproved whole blood rapid enzyme immunoassay ( EIA ) screen enrollment Reports anal sex man last 12 month Able understand pas comprehension assessment questionnaire Able understand sign write informed consent form , must obtain prior initiation study procedure Able understand English Adequate renal function : calculated creatinine clearance least 70 mL/min Hepatic transaminase ( AST ALT ) less equal 2x upper limit normal ( ULN ) Total bilirubin less equal 1.5 mg/dL Absolute neutrophil count least 1,500/mm3 ; Platelets least 100,000/mm3 ; Hemoglobin least 9.5 g/dL Serum amylase less equal 1.5 x ULN Biochemical profile : within normal limit serum phosphorus , potassium , sodium , calcium . Hepatitis B surface antigen negative Normal urine dipstick urinalysis ( UA ) Active untreated syphilis Current uncontrolled hypertension ( blood pressure &gt; 160/100 mmHg ) Mutually monogamous &gt; one year know HIV antibody negative partner History chronic renal disease , know osteoporosis , osteomalacia , osteopenia Current expect participation longitudinal HIV behavioral biomedical research study Current HIV antiretroviral use Receiving plan receive ongoing therapy nephrotoxic agent experimental/investigational agent Previous expect requirement administration immunosuppressive/ immunomodulatory therapy ( e.g . chronic systemic steroid , interferon , interleukin , chemotherapy , radiation ) . Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Current alcohol substance abuse judge investigator potentially interfere participant compliance . Imminently lifethreatening medical condition ( malignancy , immunosuppressive disease [ e.g . lymphoma ] ) , serious disease condition ( e.g . cardiovascular , renal , diabetes ) within last 5 year unstable and/or require chronic medication would impede compliance study requirement complicate interpretation adverse event Expected noncompliant study visit plan move within 24 month area study conduct Any clinical social condition , prior therapy , occupation , responsibility , , opinion investigator , would interfere , serve contraindication study participation compliance dosing requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>